We estimate that the CEO of ACADIA PHARMACEUTICALS INC ($ACAD), Catherine Owen, received a compensation of $8,256,518 in 2025.
These estimates are based on a new DEF14A filing, filed with the SEC on April 23, 2026. Note that parsing errors may occur.
You can track $ACAD on Quiver Quantitative's $ACAD stock dashboard.
$ACAD Stock Insider Trading Activity
$ACAD Stock insiders have traded $ACAD stock on the open market 15 times in the past 6 months. Of those trades, 0 have been purchases and 15 have been sales.
Here’s a breakdown of recent trading of $ACAD stock by insiders over the last 6 months:
- JAMES M DALY sold 30,000 shares for an estimated $670,983
- MARK C. SCHNEYER (EVP, CHIEF FINANCIAL OFFICER) has made 0 purchases and 5 sales selling 20,356 shares for an estimated $462,389.
- ADAMS CATHERINE OWEN (Chief Executive Officer) sold 11,641 shares for an estimated $249,932
- JENNIFER J RHODES (EVP, CHIEF LEGAL OFFICER, SEC) has made 0 purchases and 2 sales selling 10,794 shares for an estimated $245,021.
- JAMES KIHARA (PRINCIPAL ACCOUNTING OFFICER) has made 0 purchases and 5 sales selling 7,056 shares for an estimated $161,514.
- ELIZABETH H.Z. THOMPSON (EVP, Head of Research & Dev) sold 3,435 shares for an estimated $73,749
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.
$ACAD Stock Hedge Fund Activity
We have seen 159 institutional investors add shares of $ACAD Stock stock to their portfolio, and 158 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- POINT72 ASSET MANAGEMENT, L.P. added 1,890,954 shares (+127.2%) to their portfolio in Q4 2025, for an estimated $50,507,381
- MARSHALL WACE, LLP removed 1,865,502 shares (-79.1%) from their portfolio in Q4 2025, for an estimated $49,827,558
- RTW INVESTMENTS, LP removed 1,851,023 shares (-20.6%) from their portfolio in Q4 2025, for an estimated $49,440,824
- CITIGROUP INC removed 1,490,386 shares (-94.7%) from their portfolio in Q4 2025, for an estimated $39,808,210
- TANG CAPITAL MANAGEMENT LLC removed 1,200,000 shares (-80.0%) from their portfolio in Q4 2025, for an estimated $32,052,000
- CITADEL ADVISORS LLC added 1,043,939 shares (+322.7%) to their portfolio in Q4 2025, for an estimated $27,883,610
- MILLENNIUM MANAGEMENT LLC removed 929,561 shares (-62.7%) from their portfolio in Q4 2025, for an estimated $24,828,574
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
$ACAD Stock Analyst Ratings
Wall Street analysts have issued reports on $ACAD in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Mizuho issued a "Outperform" rating on 02/23/2026
- UBS issued a "Buy" rating on 01/06/2026
- Citigroup issued a "Buy" rating on 01/06/2026
- JP Morgan issued a "Overweight" rating on 11/17/2025
- Needham issued a "Buy" rating on 11/06/2025
To track analyst ratings and price targets for $ACAD Stock, check out Quiver Quantitative's $ACAD forecast page.
$ACAD Stock Price Targets
Multiple analysts have issued price targets for $ACAD recently. We have seen 13 analysts offer price targets for $ACAD in the last 6 months, with a median target of $34.0.
Here are some recent targets:
- Tazeen Ahmad from B of A Securities set a target price of $29.0 on 03/25/2026
- Tessa Romero from JP Morgan set a target price of $34.0 on 03/04/2026
- Paul Matteis from Stifel set a target price of $24.0 on 02/26/2026
- Brian Abrahams from RBC Capital set a target price of $30.0 on 02/26/2026
- Jason N. Butler from Citizens set a target price of $35.0 on 02/26/2026
- Ritu Baral from TD Cowen set a target price of $37.0 on 02/26/2026
- Rudy Li from Wolfe Research set a target price of $33.0 on 02/24/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
